Literature DB >> 32148193

Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer.

Emi Tanaka1, Daisuke Uchida1,2, Hidenori Shiraha1, Hironari Kato1, Atsushi Ohyama1, Masaya Iwamuro1, Masami Watanabe2, Hiromi Kumon3, Hiroyuki Okada1.   

Abstract

BACKGROUND: We previously demonstrated that the reduced expression in immortalized cells (REIC)/dikkopf-3 (Dkk-3) gene was downregulated in various malignant tumors, and that an adenovirus vector carrying the REIC/Dkk-3 gene, termed Ad-REIC induced cancer-selective apoptosis in pancreatic cancer and hepatocellular carcinoma.
OBJECTIVE: In this study, we examined the therapeutic effects of Ad-REIC in biliary cancer using a second- generation Ad-REIC (Ad-SGE-REIC).
METHODS: Human biliary cancer cell lines (G-415, TFK-1) were used in this study. The cell viability and apoptotic effect of Ad-SGE-REIC were assessed in vitro using an MTT assay and Hoechst staining. The anti-tumor effect in vivo was assessed in a mouse xenograft model. We also assessed the therapeutic effects of Ad-SGE-REIC therapy with cisplatin. Cell signaling was assessed by Western blotting.
RESULTS: Ad-SGE-REIC reduced cell viability, and induced apoptosis in biliary cancer cell lines via the activation of the c-Jun N-terminal kinase pathway. Ad-SGE-REIC also inhibited tumor growth in a mouse xenograft model. This effect was further enhanced in combination with cisplatin.
CONCLUSION: Ad-SGE-REIC induced apoptosis and inhibited tumor growth in biliary cancer cells. REIC/Dkk-3 gene therapy using Ad-SGE-REIC is an attractive therapeutic tool for biliary cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  REIC/Dkk-3; apoptosis; biliary cancer; chemotherapy; cisplatin; gene therapy.

Mesh:

Substances:

Year:  2020        PMID: 32148193     DOI: 10.2174/1566523220666200309125709

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  6 in total

1.  Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.

Authors:  Shuyu Wang; Dali Xu; Bo Gao; Shuhan Yan; Yiwei Sun; Xinxing Tang; Yanjia Jiao; Shan Huang; Shumei Zhang
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

2.  Identification of Diagnostic Markers for Breast Cancer Based on Differential Gene Expression and Pathway Network.

Authors:  Shumei Zhang; Haoran Jiang; Bo Gao; Wen Yang; Guohua Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-12

3.  Exploration of Lung Cancer-Related Genetic Factors via Mendelian Randomization Method Based on Genomic and Transcriptomic Summarized Data.

Authors:  Nitao Cheng; Xinran Cui; Chen Chen; Changsheng Li; Jingyu Huang
Journal:  Front Cell Dev Biol       Date:  2021-12-06

4.  DKK3, Downregulated in Invasive Epithelial Ovarian Cancer, Is Associated with Chemoresistance and Enhanced Paclitaxel Susceptibility via Inhibition of the β-Catenin-P-Glycoprotein Signaling Pathway.

Authors:  Que Thanh Thanh Nguyen; Hwang Shin Park; Tae Jin Lee; Kyung-Mi Choi; Joong Yull Park; Daehan Kim; Jae Hyung Kim; Junsoo Park; Eun-Ju Lee
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

5.  Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile.

Authors:  Shumei Zhang; Jingyu Zhang; Qichao Zhang; Yingjian Liang; Youwen Du; Guohua Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-31

6.  Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report.

Authors:  Mingrui Wu; Lan Liang; Xiaotian Dai
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.